Pfizer revenue shoots up 3% to $15 billion
Compartilhar
Pfizer (NYSE:PFE) reported second-quarter revenue of $15.03 billion, up 3%, while adjusted diluted earnings reached $0.77 per share.
Pfizer (NYSE:PFE) reported second-quarter revenue of $15.03 billion, up 3%, while adjusted diluted earnings reached $0.77 per share.
In a significant move for pharmaceutical transparency, the Bristol Myers Squibb-Pfizer Alliance announced that Eliquis® (apixaban), one of the world’s most widely prescribed blood thinners, will soon be available through Mark Cuban’s direct-to-consumer pharmacy.
Pfizer (NYSE:PFE) announced on June 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for HYMPAVZI® (marstacimab-hncq). The therapy is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A or B, both with and without inhibitors.
Pfizer (NYSE:PFE) and Astellas announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for the perioperative use of Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab).
